Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 17/20 | 0.62 |
| ▸ | NR1H2 | P55055 | 17/20 | 0.62 |
| ▸ | NR1H3 | Q13133 | 17/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.62 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | PTGFR | P43088 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL799660 | 0.84 | RXRA (0.50) | RXRANR1H2NR1H3NR1I2PTGES | |
| SCHEMBL805144 | 0.80 | RXRA (0.43) | RXRANR1H2NR1H3NR1I2PTGES | |
| SCHEMBL778922 | 0.80 | GABRA2 (0.50) | RXRANR1H2NR1H3NR1I2 | |
| SCHEMBL12821546 | 0.79 | RXRA (0.80) | RXRANR1H2NR1H3NR1I2 | |
| SCHEMBL12821545 | 0.79 | RXRA (0.79) | RXRANR1H2NR1H3NR1I2 | |
| SCHEMBL16407949 | 0.78 | NR1H2 (0.89) | RXRANR1H2NR1H3NR1I2 | |
| Bms-852927 SCHEMBL779963 | 0.77 | NR1H2 (1.00) | RXRANR1H2NR1H3NR1I2 | |
| SCHEMBL16407948 | 0.75 | NR1H2 (0.89) | RXRANR1H2NR1H3NR1I2 | |
| SCHEMBL19567526 | 0.74 | NR1H2 (0.65) | RXRANR1H2NR1H3NR1I2 | |
| SCHEMBL780880 | 0.74 | NR1H2 (1.00) | RXRANR1H2NR1H3NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435410-B1 | LXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2017-01-18 | — | — | EP | disclosed |
| EP-2435410-B1 | LXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20160280661-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160280661-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160280661-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2016-09-29 | — | — | US | disclosed |
| US-20150299136-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150299136-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150299136-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-22 | — | — | US | disclosed |
| US-20140163081-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163081-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163081-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-12 | — | — | US | disclosed |
| US-8618154-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2435410-A2 | LXR MODULATORS | Exelixis Patent Company LLC (US) | 2012-04-04 | — | — | EP | disclosed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | disclosed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | disclosed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | disclosed |
| WO-2010138598-A2 | LXR MODULATORS | EXELIXIS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138598-A2 | LXR MODULATORS | EXELIXIS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163081-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | RXRA 10/4885NR1H2 2/4885NR1H3 1/4885 |
| US-20120071534-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | RXRA 10/4885NR1H2 2/4885NR1H3 1/4885 |
| US-20150299136-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | RXRA 10/4885NR1H2 2/4885NR1H3 1/4885 |
| US-20160280661-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | RXRA 10/4885NR1H2 2/4885NR1H3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.